Improvement of High-sensitivity Inflammation-based Glasgow Prognostic Score by Gastrectomy Is a Favorable Prognostic Factor in Patients with Gastric Cancer

被引:0
作者
Takeno, Shinsuke [1 ]
Hashimoto, Tatsuya [1 ]
Shibata, Ryosuke [1 ]
Maki, Kenji [1 ]
Shiwaku, Hironari [1 ]
Yamana, Ippei [1 ]
Yamashita, Risako [1 ]
Yamashita, Yuichi [1 ]
机构
[1] Fukuoka Univ, Fac Med, Dept Surg Gastroenterol, Fukuoka 8140180, Japan
关键词
High-sensitivity Glasgow prognostic score; surgery; gastric cancer; C-reactive protein; albumin; PHASE-III TRIAL; CELL LUNG-CANCER; ADJUVANT CHEMOTHERAPY; CURATIVE RESECTION; SURVIVAL; SURGERY; 5-FLUOROURACIL; DISEASE; TUMOR; GPS;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: The aim of the present study was to clarify the efficacy of inflammation-based Glasgow prognostic score after surgery in patients with gastric cancer and to determine clinicopathological factors affecting score improvement. Patients and Methods: Participants in this retrospective study were 236 patients with gastric cancer who underwent gastrectomy at the Fukuoka University Hospital. The high-sensitivity inflammation-based Glasgow prognostic score (HS-GPS) (cut-off values: 0.3 mg/dl for C-reactive protein; 3.5 g/dl for albumin) were calculated before and 1 month after surgery, and correlated to clinicopathological parameters and prognosis after surgery. Results: HS-GPS was classified as normal (score 0) in 162 patients and abnormal (score 1 or 2) in 74 patients. Out of the 162 patients with normal HS-GPS before surgery, 62 showed abnormal HS-GPS after surgery, while 26 of the 74 patients with abnormal HS-GPS before surgery improved to normal HS-GPS postoperatively. Abnormal HS-GPS before (p<0.0001) and after (p=0.0002) surgery were unfavorable prognostic factors in univariate analysis. HS-GPS after surgery was an independent prognostic factor (p=0.0324) in multivariate analysis, but HS-GPS before surgery was not. In the subgroup with abnormal HS-GPS before surgery (but not normal HS-GPS before surgery), improved HS-GPS after surgery had favorable prognostic impact in both uni- (p=0.0039) and multivariate analyses (p=0.0032). Conclusion: HS-GPS after surgery may be a valuable prognostic factor in patients with gastric cancer. Supplemental therapy represented by adjuvant chemotherapy might be required for gastric cancer p showing no improvement in HS-GPS after gastrectomy.
引用
收藏
页码:5695 / 5702
页数:8
相关论文
共 24 条
  • [1] The relationship between hypoalbuminaemia, tumour volume and the systemic inflammatory response in patients with colorectal liver metastases
    Al-Shaiba, R
    McMillan, DC
    Angerson, WJ
    McArdle, CS
    Horgan, P
    [J]. BRITISH JOURNAL OF CANCER, 2004, 91 (02) : 205 - 207
  • [2] Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer:: 7-year results of the FFCD randomized phase III trial (8801)
    Bouché, O
    Ychou, M
    Burtin, P
    Bedenne, L
    Ducreux, M
    Lebreton, G
    Baulieux, J
    Nordlinger, B
    Martin, C
    Seitz, JF
    Tigaud, JM
    Echinard, E
    Stremsdoerfer, N
    Milan, C
    Rougier, P
    [J]. ANNALS OF ONCOLOGY, 2005, 16 (09) : 1488 - 1497
  • [3] Brennan MF, 1996, SEMIN ONCOL, V23, P352
  • [4] Preoperative but not postoperative systemic inflammatory response correlates with survival in colorectal cancer
    Crozier, J. E. M.
    Mckee, R. F.
    McArdle, C. S.
    Angerson, W. J.
    Anderson, J. H.
    Horgan, P. G.
    McMillan, D. C.
    [J]. BRITISH JOURNAL OF SURGERY, 2007, 94 (08) : 1028 - 1032
  • [5] Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study)
    De Vita, F.
    Giuliani, F.
    Orditura, M.
    Maiello, E.
    Galizia, G.
    Di Martino, N.
    Montemurro, F.
    Carteni, G.
    Manzione, L.
    Romito, S.
    Gebbia, V.
    Ciardiello, F.
    Catalano, G.
    Colucci, G.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 (08) : 1354 - 1358
  • [6] Adjuvant chemotherapy in completely resected gastric cancer: A Randomized phase III trial conducted by GOIRC
    Di Costanzo, Francesco
    Gasperoni, Silvia
    Manzione, Luigi
    Bisagni, Giancarlo
    Labianca, Roberto
    Bravi, Stefano
    Cortesi, Enrico
    Carlini, Paolo
    Bracci, Raffaella
    Tomao, Silverio
    Messerini, Luca
    Arcangeli, Annarosa
    Torri, Valter
    Bilancia, Domenico
    Floriani, Irene
    Tonato, Maurizio
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (06): : 388 - 398
  • [7] Comparison of the prognostic value of tumour and patient related factors in patients undergoing potentially curative resection of gastric cancer
    Dutta, Sumanta
    Crumley, Andrew B. C.
    Fullarton, Grant M.
    Horgan, Paul G.
    McMillan, Donald C.
    [J]. AMERICAN JOURNAL OF SURGERY, 2012, 204 (03) : 294 - 299
  • [8] Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
    Ferlay, Jacques
    Shin, Hai-Rim
    Bray, Freddie
    Forman, David
    Mathers, Colin
    Parkin, Donald Maxwell
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (12) : 2893 - 2917
  • [9] Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer
    Forrest, LM
    McMillan, DC
    McArdle, CS
    Angerson, WJ
    Dunlop, DJ
    [J]. BRITISH JOURNAL OF CANCER, 2004, 90 (09) : 1704 - 1706
  • [10] Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer
    Forrest, LM
    McMillan, DC
    McArdle, CS
    Angerson, WJ
    Dunlop, DJ
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 (06) : 1028 - 1030